Results 51 to 60 of about 8,373 (204)

Producing amyloid fibrils in vitro: A tool for studying AL amyloidosis

Biochemistry and Biophysics Reports, 2023
Amyloid light-chain (AL) amyloidosis is the second most common form of systemic amyloidosis which is characterized by a high level of mortality and no effective treatment to remove fibril deposition.
Daria V. Sizova, Steve Raiker, Deaneira Lakheram, Vishwanatha Rao, Andrew Proffitt, Yazen Jmeian, Walter Voegtli, Melissa Batonick   +7 more
doaj   +1 more source

Successful management of refractory pleural effusion due to systemic immunoglobulin light chain amyloidosis by vincristine adriamycin dexamethasone chemotherapy: a case report

Journal of Medical Case Reports, 2010
Introduction Refractory pleural effusion in systemic immunoglobulin light chain amyloidosis without cardiac decompensation is rarely reported and has a poor prognosis in general (a median survival of 1.6 months).
Mima Akira, Murakami Taichi, Mimura Rokuro, Araki Makoto, Kishi Seiji, Hoshina Azusa, Kondo Makiko, Ikeda Masaki, Nishioka Keisuke, Takeoka Hiroya, Araoka Toshikazu, Nagai Kojiro, Abe Hideharu, Doi Toshio   +13 more
doaj   +1 more source

Concurrent light chain amyloidosis and proximal tubulopathy: Insights into different aggregation behavior—A case report

eJHaem, 2022
Due to differences in the protein folding mechanisms, it is exceedingly rare for amyloid light chain (AL) amyloidosis and monoclonal gammopathy of renal significance (MGRS) to coexist.
Simone Feurstein, Julian Zoller, Constantin Schwab, Sarah Schreiner, Heiko Mundt, Iris Breitkreutz, Brigitte Schneider, Jörg Beimler, Martin Zeier, Rüdiger Waldherr, Stefan Gröschel, Carsten Müller‐Tidow, Stefan O. Schönland, Ute Hegenbart   +13 more
doaj   +1 more source

Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach. [PDF]

J Adv Pract Oncol, 2019
Systemic immunoglobulin light-chain (AL) amyloidosis is a rare disorder arising from a plasma cell clone that produces misfolded immunoglobulin light chains, which are deposited in various tissues and organs as amyloid fibrils. Signs and symptoms are typically vague and overlap with those arising from other common diseases; consequently, diagnosis of ...
Hwa YL, Fogaren T, Sams A, Faller DV, Stull DM, Thuenemann S, Mendelson L.   +6 more
europepmc   +4 more sources

A stepwise data interpretation process for renal amyloidosis typing by LMD-MS

BMC Nephrology, 2022
Backgrounds Systemic amyloidosis is classified according to the deposited amyloid fibril protein (AFP), which determines its best therapeutic scheme. The most common type of AFP found are immunoglobulin light chains.
Ming Ke, Xin Li, Lin Wang, Shuling Yue, Beibei Zhao   +4 more
doaj   +1 more source

Cardiac Amyloidosis: Clinical Features, Pathogenesis, Diagnosis, and Treatment [PDF]

Türk Patoloji Dergisi
Cardiac amyloidosis is a type of amyloidosis that deserves special attention as organ involvement significantly worsens the prognosis. Cardiac amyloidosis can be grouped under three main headings: immunoglobulin light chain (AL) amyloidosis that is ...
Asuman ARGON, Deniz NART, Funda YILMAZ BARBET   +2 more
doaj   +1 more source

Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis. [PDF]

PLoS ONE, 2007
BACKGROUND: Amyloid is insoluble aggregated proteins deposited in the extra cellular space. About 25 different proteins are known to form amyloid in vivo and are associated with severe diseases such as Alzheimer's disease, prion diseases and type-2 ...
Stina Enqvist, Knut Sletten, Fred J Stevens, Ulf Hellman, Per Westermark   +4 more
doaj   +1 more source

Light-chain amyloidosis with dysphagia as the main symptom: a case report

Journal of Medical Case Reports
Background Immunoglobulin light-chain amyloidosis is a relatively rare condition with a worldwide incidence of 5.1–12.8 cases per million person-years (Baker, 2022).
Maomao Ai, Tao Lin, Ruoyu Guo, Haiyao Zheng, Haiyan Deng, Feng Yu   +5 more
doaj   +1 more source

From RNA to DNA: How Cargo Identity Reprograms Lipid Nanoparticle Architecture and Function

Advanced Healthcare Materials, EarlyView.
The evolution of lipid nanoparticles (LNPs) spans from RNA‐LNPs, used in mRNA vaccines, to DNA‐LNPs, ideal for gene therapies. Emerging bionano architectures, decorated with DNA and plasma proteins, pave the way for advanced DNA‐based therapies that are more stable, targeted, and customizable.
Erica Quagliarini, Daniela Pozzi, Giulio Caracciolo   +2 more
wiley   +1 more source

Systemic Immunoglobulin Light Chain Amyloidosis Presenting as Painful Penile Ulcers

Annals of Internal Medicine: Clinical Cases, 2022
Immunoglobulin light chain (AL) amyloidosis is a systemic form of amyloidosis that commonly affects the heart, kidney, liver, and nervous system. Penile involvement in AL amyloidosis is rare and thus often not considered in the differential diagnosis for
Crystal Lihong Yan, Fireneh N. Beshah, Karen Eliahu, James E. Hoffman   +3 more
doaj   +1 more source